Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

If New COVID-19 Vaccine Recommendations Land In the United States, Do They Make Sound?

Executive Summary

CDC’s director signs off on FDA’s proposed updates to COVID-19 vaccines, marking the country’s second attempt to simplify the administration schedule in a effort to increase vaccine uptake. There’s little evidence that this latest strategy shift will be any more successful.

You may also be interested in...



COVID Vaccine Transition Planning: Price Does Not Come Up At ACIP

US CDC is starting to prepare for the transition of COVID vaccine deliver to more traditional commercial channels. It is noteworthy that the first discussion of what will change did not include any talk of prices.

Supplemental Filings: Pink Sheet’s Notebook on Elon vs. FDA, Audio vs. Video, and More

Califf tweaks his misinformation stump speech, FDA adds to the Twitter COVID vaccine confusion with a tweet to Elon Musk, generic firms are schooled on the difference between a teleconference and a video conference, and other observations from Pink Sheet reporters’ notebooks.

Now and Later: Administration Struggles To Cement COVID Booster Strategy Amid Evolving Pandemic

US FDA was trying to focus people on a one-booster-per year, updated fall COVID vaccine campaign to address what they perceive as the public’s inoculation exhaustion, but as BA.5 seems to be sending the US into another surge the White House is pushing a summer booster campaign.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel